



10th Anniversary of Biomedicines—Ophthalmology Disorders

Guest Editors:

Prof. Dr. Gabriele Thumann

1. Department of
Ophthalmology, University
Hospitals of Geneva, Geneva,
Switzerland

2. Experimental Ophthalmology,
University of Geneva, Geneva,
Switzerland

Dr. Martina Kropp

1. Department of
Ophthalmology, University
Hospitals of Geneva, Geneva,
Switzerland

2. Experimental Ophthalmology,
University of Geneva, Geneva,
Switzerland

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

This Special Issue aims to publish a Special Issue entitled “10th Anniversary of Biomedicines— Gene Therapy in Ophthalmology Disorders”. More than 200 million people worldwide are suffering from severe vision loss. For about 30% of patients suffering from neurodegenerative diseases, treatment options are limited. This includes inherited and frequent noncommunicable diseases such as age-related macular degeneration (AMD) or glaucoma. Gene therapy opens up new avenues in the treatment of these disorders. The eye is particularly interesting for gene therapy due to its accessibility, small size and immune privilege, however, the high complexity of the organ, especially the neuroretina, is a challenge for the development of efficient approaches. Nevertheless, multiple studies are ongoing to analyze approaches to treating monogenetic inherited diseases, such as retinitis pigmentosa, and complex diseases such as AMD, encompassing viral and nonviral treatments, ex and in vivo approaches. We invite the submission of both original articles that report preclinical and clinical studies and reviews, in order to provide an overview on the current state of the art.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI